Mechanism-based 3rd Generation Quinoline-3-carboxamide HDAC4 Inhibitor for Metastatic Castration-resistant Prostate Cancer

Case ID:
C17054

Value Proposition:

·        Metastatic castration-resistant prostate cancer (mCRPC) treatment that offers reduced side effects due to its mechanism of action (MoA)

·        HDAC4 inhibition prevents the upregulation of stress survival pathways, which in turn may prevent metastases in mCRPC

·        Similar anti-cancer agents must be dosed at lower concentrations due to the harsh side effects, which may not kill all tumors and may allow for metastases

·         With reduced side effects, this drug can be safely dosed at higher levels, resulting in increased anti-tumor efficacy


Technology Description

·        Researchers at Johns Hopkins have developed a Tasquinimod-like therapeutic for mCRPC that allows for higher dosing and serum levels of cancer-treating agent, but without the side effects associated with Tasquinimod

·        This drug candidate downregulates HDAC4, which is likely to epigenetically prevent the upregulation of the stress survival pathways needed for tumor angiogenesis that supports metastases

·        The data demonstrates that in a rodent xenograft model for castration-resistant prostate cancer, this treatment maintains HDAC4 inhibition with reduced side effects, allowing for higher daily drug dosing and increased anti-tumor efficacy


Unmet Need

·        Prostate cancer, globally, is the second leading cause of new cancer cases diagnosed in men, with approximately 50% leading to metastatic prostate cancer.

·        Current treatments include chemotherapy, hormone therapy, radiation therapy, and immunotherapies, though each has its own array of side effects and efficacy challenges.

·        Side effects can force doctors to give less than optimal therapeutic doses of these drugs to patients, which results in less than optimal tumor reduction.

·        Therefore, there is a strong need for prostate cancer drugs to be developed with fewer off-target effects and higher anti-tumor efficacy.


Stage of Development

·        Studies have been completed in animals to demonstrate efficacy and MoA


Data Availability


·        Data available upon request


Publication

N/A

Patent Information:
Title App Type Country Serial No. Patent No. File Date Issued Date Expire Date Patent Status
COMPOUNDS FOR TREATMENT OF CANCER PCT: Patent Cooperation Treaty European Patent Office 22912665.1   12/20/2022     Pending
COMPOUNDS FOR TREATMENT OF CANCER PCT: Patent Cooperation Treaty Australia 2022421214   12/20/2022     Pending
COMPOUNDS FOR TREATMENT OF CANCER PCT: Patent Cooperation Treaty Canada 3,241,699   12/20/2022     Pending
COMPOUNDS FOR TREATMENT OF CANCER PCT: Patent Cooperation Treaty United States 18/721,824   6/19/2024     Pending
Inventors:
Category(s):
Get custom alerts for techs in these categories/from these inventors:
For Information, Contact:
Vera Sampels
vsampel2@jhu.edu
410-614-0300
Save This Technology:
2017 - 2022 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by Inteum